80
%
1
0
0
1
80
%
1
0
0
1
The Karnofsky Performance Status (KPS) scale is one of the oldest and most widely used tools for assessing the functional capacity of cancer patients. Developed by Dr. David A. Karnofsky and colleagues in 1949, this scale quantifies a patient's general well-being and ability to perform activities of daily living on a scale from 0 (dead) to 100 (fully functional).
Functional status assessment is a cornerstone of oncologic care, influencing virtually every aspect of cancer management from treatment selection to prognosis estimation. A patient's performance status is often the single most important factor in determining eligibility for chemotherapy, radiation therapy, clinical trials, and surgical interventions. Patients with poor performance status have higher treatment-related mortality and lower response rates.
The KPS scale uses 11 levels at 10-point intervals, grouped into three broad categories: patients able to carry on normal activity and work (KPS 80-100), patients unable to work but able to live at home with varying amounts of assistance (KPS 50-70), and patients unable to care for themselves requiring institutional or hospital-equivalent care (KPS 0-40). Each level has a specific clinical description that guides consistent assignment.
In oncology practice, a KPS of 60 or higher is generally considered the minimum threshold for receiving active chemotherapy. Most clinical trials require a KPS of at least 70 for enrollment. A KPS below 50 is associated with a median survival of approximately 8 weeks in many cancer types, and at this level, the focus typically shifts from curative or disease-modifying treatment to palliative care.
The KPS has been validated as an independent prognostic factor across virtually all cancer types, including lung cancer, breast cancer, colorectal cancer, brain tumors, hematologic malignancies, and others. In multivariate analyses, KPS consistently predicts overall survival, treatment response, and quality of life outcomes. A decline in KPS over time is a strong predictor of poor prognosis.
While the ECOG Performance Status scale (0-5) has become more popular in clinical trials due to its simplicity, the KPS provides finer gradation and is particularly useful for detecting subtle changes in functional status over time. The two scales are approximately interconvertible, with established mapping tables used in clinical practice and research. KPS remains the standard in many radiation oncology, palliative care, and prognostic scoring systems.
The Karnofsky Performance Status scale assigns a score from 0 to 100 in 10-point increments:
Group: 1=Functional (80-100), 2=Ambulatory (50-70), 3=Dependent (0-40). Chemo eligible: 1=Yes (>=60), 0=No.
A KPS of 80-100 (Group 1) indicates the patient is largely functional and can participate in normal activities. Eligible for most treatments and clinical trials. A KPS of 50-70 (Group 2) indicates the patient needs varying degrees of assistance but remains ambulatory. May still be eligible for some treatments. A KPS of 0-40 (Group 3) indicates the patient is unable to care for themselves. Focus is typically on comfort care and symptom management.
Inputs
Results
KPS 80: Patient can perform normal activities with effort. Eligible for chemotherapy and most clinical trials.
Inputs
Results
KPS 30: Severely disabled, hospitalization indicated. Not eligible for chemotherapy. Focus on palliative care.
KPS is a standardized scale from 0-100 that quantifies a cancer patient's functional capacity and ability to perform daily activities. It was developed in 1949 and remains one of the most widely used performance measures in oncology.
Generally, a KPS of 60 or higher is the minimum threshold for active chemotherapy. Most clinical trials require KPS 70 or above. Below 60, the risks of treatment often outweigh potential benefits.
KPS uses an 11-point scale (0-100 in 10-point intervals) while ECOG uses a simpler 6-point scale (0-5). KPS provides finer gradation. The approximate conversion is: KPS 100=ECOG 0, KPS 80-90=ECOG 1, KPS 60-70=ECOG 2, KPS 40-50=ECOG 3, KPS 10-30=ECOG 4, KPS 0=ECOG 5.
Yes, KPS is assigned by clinician judgment based on patient interview and observation. Inter-observer variability exists, though it is generally acceptable. Training and experience improve consistency.
KPS is one of the strongest independent predictors of survival across cancer types. Patients with KPS below 50 typically have median survival of weeks to a few months. KPS above 80 is associated with significantly better outcomes.
Yes, KPS should be reassessed regularly. Declining KPS suggests disease progression or treatment toxicity. Improving KPS may indicate treatment response.
While developed for cancer, KPS has been adapted for use in other conditions including HIV/AIDS, stroke, neurological diseases, and critical care. It provides a general measure of functional impairment applicable across many diseases.
KPS 70 means the patient cares for themselves but cannot carry on normal work or activities. KPS 80 means the patient can perform normal activities but with extra effort and some symptoms.
KPS is a standard eligibility criterion and stratification factor in oncology trials. It ensures enrolled patients have adequate functional capacity to tolerate treatment and allows comparison of outcomes across different performance groups.
KPS below 40 indicates the patient is disabled and requires special care. At this level, the focus typically shifts to comfort care, symptom management, and hospice referral rather than active disease treatment.
Roboculator Team
The Roboculator Team explains calculations, planning tools, and practical formulas in clear language for real-life situations.
How helpful was this calculator?
Be the first to rate!
ECOG Performance Status
Health Risk Assessment & Quality of Life
Katz Index of Independence in ADL
Health Risk Assessment & Quality of Life
Lawton-Brody IADL Scale
Health Risk Assessment & Quality of Life
Falls Risk Calculator
Health Risk Assessment & Quality of Life
Morse Fall Scale
Health Risk Assessment & Quality of Life
Braden Scale (Pressure Ulcer Risk)
Health Risk Assessment & Quality of Life
